NEW YORK, May 13, 2013 — /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industry http://www.reportlinker.com/p01171136/PharmaSphere-Early-Stage-Technology-Transfer-Collaborations—Enabling-Platform-Technologies–Deal-Synergies-between-Academia-and-the-Pharmaceutical-Industry.html#utm_source=prnewswireutm_medium=prutm_campaign=Drug_and_Medication
PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industry
Summary
The PharmaSphere, Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open RD ecosystem.
Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).
Scope
- Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms – Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas – Discussion of the unsustainability of the current drug research model and how Big Pharma’s embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery – Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer – Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies – Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, ‘Big Data’ and drug recycling/repurposing approaches Highlights
Key Questions Answered
- What are the reasons for increased activity in strategic deals with academia by leading pharmaceutical companies and promising biotechs? – What are the deal terms of these collaboration agreements? – What therapeutic areas and geographic markets are pharmaceutical companies targeting to partner with academic research institutions? – What proprietary platforms and enabling technologies are these pharmaceutical companies trying to access?
Key Findings
- With the patent cliff and high RD costs eroding corporate profitability, pharmaceutical companies will look for ways to replenish their pipelines by reaching out to academia in search of novel drug platforms – Despite the FDA approving 39 new drugs in 2012, the innovation gap continues, as many of these medicines are ‘me-too’ drugs, or orphan drugs indicated to treat small segments of the population suffering from rare diseases – Difficulty accessing capital and the continued economic recession have led to a deal adverse environment resulting in deals to decline on a global basis – Oncology, CNS, immunology and infectious diseases still remain hot therapeutic areas to strike licensing deals with academia
Key Benefits
- Analyze and track the strategies that these pharmaceutical companies are using to gain share in an increasingly competitive marketplace – Target academic institutions with novel and proprietary technologies to maximize opportunities for strategic investment or partnerships – Formulate effective licensing strategies by understanding the various factors and deal terms considered when structuring tech-transfer partnerships – Use information as an independent source for your due diligence and transaction strategies
Table of Contents
1 Table of Contents 1 1.1 List of Tables 4 1.2 List of Figures 4 2 Executive Summary 5 3 Introduction 7 3.1 Catalyst 7 3.2 Related Reports 8 3.3 About PharmaSphere Report Series 8 4 A Changing and Challenging Deal Making Landscape 9 4.1 Overview 9 4.2 Deal Drivers 10 4.2.1 The Patent Cliff 10 4.2.2 Deal-Adverse Environment 13 4.2.3 Spike in Regulatory Approvals but Innovation Gap Continues 16 4.2.4 FDA’s Proposal to Lower Regulatory Standards in Early-Stage Alzheimer’s Research 17 4.2.5 More Stringent Regulatory Regime in a Post-Vioxx and Avandia World 17 4.2.6 Viewpoint: Vioxx and Avandia Cases 18 5 An Unsustainable RD Paradigm 20 5.1 Big Pharma’s Embrace of Disruptive Innovation May Fix Broken RD Model 20 5.1.1 Pre-Competitive Information Sharing 20 5.1.2 Open-Source Patient Data 21 5.1.3 ‘Big Data’ and Drug Discovery 22 5.1.4 Tech Transfer in Action: Astellas Pharma Taps IT for Drug Discovery 22 5.1.5 Drug Recycling 22 5.1.6 Viewpoint: Drug Repurposing at NCATS 23 5.1.7 Tech Transfer in Action: Roche Broad Join to Bring Failed Drugs Back from the Dead 23 6 Major Global Technology Transfer Alliances 24 6.1 The Bayh-Dole Act of 1980 24 6.2 Deals Overview 25 6.3 Biscayne Pharma Enters into Licensing Agreement with University of Miami for Growth Hormone-Releasing Technology 29 6.3.1 Deal Summary 29 6.3.2 Deal Analysis 29 6.4 Genoa Pharma Enters into Research Agreement with McMaster University for IPF 30 6.4.1 Deal Summary 30 6.4.2 Deal Analysis 30 6.5 AstraZeneca Partners with Vanderbilt University for Neuroscience Drug Discovery 31 6.5.1 Deal Summary 31 6.5.2 Deal Analysis 31 6.6 Trovagene Grants License for NPM1 Marker for AML to Duke University 32 6.6.1 Deal Summary 32 6.6.2 Deal Analysis 32 6.7 Synthetic Biologics and University of Texas Ink Research Deal to Fight Pertussis 33 6.7.1 Deal Summary 33 6.7.2 Deal Analysis 33 6.8 BMS and Vanderbilt University Sign Deal to Develop Drugs for Parkinson’s 34 6.8.1 Deal Summary 34 6.8.2 Deal Analysis 34 6.9 AstraZeneca and Broad Institute Partner to Advance Discovery of Antibacterial and Antiviral Agents 35 6.9.1 Deal Summary 35 6.9.2 Deal Analysis 35 6.10 Bayer HealthCare Opens New Lab Space – The CoLaborator – for Biotech Startups 36 6.10.1 Deal Summary 36 6.10.2 Deal Analysis 36 6.11 Novartis Enters into Licensing Agreement with Penn for CART-19 37 6.11.1 Deal Summary 37 6.11.2 Deal Analysis 37 6.12 Sanofi and BWH Agree to Develop Antibodies for Type 1 Diabetes 38 6.12.1 Deal Summary 38 6.12.2 Deal Analysis 38 6.13 AstraZeneca and Leading Academic Organizations Collaborate on Alzheimer’s Research 39 6.13.1 Deal Summary 39 6.13.2 Deal Analysis 39 6.14 Novo Nordisk Enters into RD Agreement with JDRF for Type 1 Diabetes 40 6.14.1 Deal Summary 40 6.14.2 Deal Analysis 40 6.15 Large Pharmas Unite with the Genome Institute of Singapore to Combat Cancer in Asian Populations 41 6.15.1 Deal Summary 41 6.15.2 Deal Analysis 41 6.15.3 Tech Transfer in Action: National University Singapore Startup AyoxxA Biosystems 42 6.16 University of Washington and ‘Big Pharma’ Join Forces to Research Drug Transporters 43 6.16.1 Deal Summary 43 6.16.2 Deal Analysis 43 6.17 Pharma and the University of Dundee Create Consortium on Cell Signaling Research 44 6.17.1 Deal Summary 44 6.17.2 Deal Analysis 44 6.18 Novo Nordisk and Oxford Join to Identify Novel Biomarkers for Rheumatoid Arthritis 45 6.18.1 Deal Summary 45 6.18.2 Deal Analysis 45 6.19 Elan Corporation and University of Cambridge Enter into Joint Venture to Discover New Therapies Targeting Neurodegenerative Disorders 46 6.19.1 Deal Summary 46 6.19.2 Deal Analysis 46 6.20 GSK and Yale Partner to Develop New Drugs Targeting Disease-Causing Proteins 47 6.20.1 Deal Summary 47 6.20.2 Deal Analysis 47 6.21 Big Pharma Companies and Research Institutions Tackle Early-Stage Research TB 48 6.21.1 Deal Summary 48 6.21.2 Deal Analysis 48 6.22 Accuray Signs Collaboration Agreement with University of Heidelberg to Provide Cutting-edge Research in Radiation Oncology 49 6.22.1 Deal Summary 49 6.22.2 Deal Analysis 49 6.23 UCB and Oxford University Join to Focus on Developing Innovative Medicines for Immunological and Neurological Disorders 50 6.23.1 Deal Summary 50 6.23.2 Deal Analysis 50 6.24 Large Pharma and King’s College London Establish a Center to Tackle Autism 51 6.24.1 Deal Summary 51 6.24.2 Deal Analysis 51 6.25 Merck Establishes an Independent Non-profit Drug Research Institute – the California Institute for Biomedical Research 52 6.25.1 Deal Summary 52 6.25.2 Deal Analysis 52 6.26 JJ and University of Queensland Develop Drugs Using Spider Venom for Treating Pain 53 6.26.1 Deal Summary 53 6.26.2 Deal Analysis 53 6.27 Sanofi and UCSF Form a Pact to Work on New Treatments for Diabetes 54 6.27.1 Deal Summary 54 6.27.2 Deal Analysis 54 6.27.3 Tech Transfer in Action: Tufts University Spin-off Anchor Therapeutics 55 7 Future Outlook 56 8 Appendix 57 8.1 Research Methodology 57 8.1.1 Coverage 57 8.1.2 Secondary Research 57 8.1.3 Expert Panel Validation 57 8.2 About the Author 58 8.2.1 Analyst 58 8.3 Director, Healthcare Industry Dynamics 58 8.4 Global Head of Healthcare Research and Consulting 58 8.5 About the Industry Dynamics Team 58 8.6 GlobalData 59 8.7 Contact Us 59 8.8 Disclosure Information 59 8.9 Disclaimer 59
List of Tables
Table 1: Recent and Upcoming US Patent Expirations with FY2011 and FY2012 Sales Data 11 Table 2: Deals Summary of Major Technology Transfer Alliances, January 2012–January 2013 26 Table 3: Biscayne Pharma University of Miami, Deal Summary, 2013 29 Table 4: Genoa Pharma McMaster University, Deal Summary, 2013 30 Table 5: AstraZeneca Vanderbilt University, Deal Summary, 2013 31 Table 6: Trovagene Duke University, Deal Summary, 2012 32 Table 7: Synthetic Biologics University of Texas, Deal Summary, 2012 33 Table 8: BMS Vanderbilt University, Deal Summary, 2012 34 Table 9: AstraZeneca Broad Institute, Deal Summary, 2012 35 Table 10: Bayer HealthCare Aronora, ProLynx, Deals Summary 2012 36 Table 11: Novartis University of Pennsylvania, Deal Summary 2012 37 Table 12: Sanofi Brigham and Women’s Hospital, Deal Summary 2012 38 Table 13: AstraZeneca Leading Academic Organizations, Deal Summary 2012 39 Table 14: Novo Nordisk JDRF, Deal Summary 2012 40 Table 15: Eli Lilly, Merck, Pfizer Genome Institute of Singapore, Deal Summary 2012 41 Table 16: AZ, Genentech, Merck University of Washington in St. Louis, Deal Summary 2012 43 Table 17: Pharma University of Dundee, Deal Summary 2012 44 Table 18: Novo Nordisk University of Oxford, Deal Summary 2012 45 Table 19: Elan Corporation University of Cambridge, Deal Summary 2012 46 Table 20: GSK Yale University, Deal Summary 2012 47 Table 21: Pharma Texas AM University and Cornell Medical College, Deal Summary 2012 48 Table 22: Accuray University of Heidelberg, Deal Summary 2012 49 Table 23: UCB Oxford University, Deal Summary 2012 50 Table 24: Eli Lilly, Janssen, Pfizer, Roche Kings College London, Deal Summary 2012 51 Table 25: Merck, Pharma Biotech Start-ups, Deal Summary 2012 52 Table 26: Johnson Johnson University of Queensland, Deal Summary 2012 53 Table 27: Sanofi University of California at San Francisco, Deal Summary 2012 54
List of Figures
Figure 1: Academic Technology Transfer Deals and Deal Values (US $m), Globally from 2007–2012 5 Figure 2: Lipitor Sales WW vs. US, 4Q11–4Q12 10 Figure 3: Pharmaceuticals and Healthcare, Number of Deals and Deal Values (US $m), Globally from September 2012 – February 2013 13 Figure 4: Pharmaceuticals Healthcare, Number of Deals by Region, February 2013 14 Figure 5: Pharmaceuticals Healthcare, Number of Deals by Therapy Area, February 2013 14 Figure 6: FDA Drug Approvals, 1995–2012 16 Figure 7: Academic Technology Transfer Deals and Deal Values (US $m), from 2007–2012 25
To order this report: Drug_and_Medication Industry: PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industry
Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001
SOURCE Reportlinker
• Read more articles by Reportlinker
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling ...
Không có nhận xét nào:
Đăng nhận xét